Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. et al
Case Number:
1:23-cv-00580
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 13, 2024
Alnylam Says It's Not A 'Patent Troll' In Vax IP Row
Alnylam Pharmaceuticals has shot back at Moderna's request for about $2.8 million in legal costs it incurred defending a patent suit over its coronavirus vaccine, saying Moderna is wrongly trying to paint it as "a pernicious patent troll."
-
October 17, 2024
Moderna Wants Fees For 'Frivolous' COVID-19 Vax Suit
Moderna is asking a Delaware federal judge to award it about $2.8 million in legal costs for its defense of claims in a patent suit brought by Alnylam Pharmaceuticals over its coronavirus vaccine, arguing the Boston-based company pursued "frivolous" claims that wasted court resources.
-
October 03, 2024
Boston Pharma Co. Drops Another Moderna Patent Suit
A Boston pharmaceutical developer once again has agreed to drop a patent lawsuit against Moderna over its popular coronavirus vaccines after losing a claim construction ruling in front of Delaware's top judge.
-
August 20, 2024
Vax Patent Battles Heat Up As Attention On Pandemic Wanes
It's been over four years since clinical trials began for COVID-19 vaccines, and while the shots have helped the pandemic recede, the lucrative technology has spurred numerous patent suits, many of which are still in the early stages. Here's a look at some of the key cases in the U.S.
-
May 30, 2023
Alnylam Widens Vaccine IP Litigation Against Pfizer, Moderna
Shortly after obtaining additional patents on vaccine delivery technology from the U.S. Patent and Trademark Office, pharmaceutical company Alnylam has expanded its infringement litigation against Pfizer and Moderna over their COVID-19 vaccines.